Uncategorized

Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.

Biogenysis, Inc. (OTC PINK:ENZC) (or the “Company”). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation Treaty (PCT) application covering its inventions relating to Anti-SARS-CoV-2 Monoclonal Antibodies.

Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application. Read More »

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)

XNK Therapeutics AB announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia.

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML) Read More »

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Read More »

Scroll to Top